METTL3 and hepatoblastoma: Cui et al. (2020) reported that miR-186 interacting with METTL3 contributed to the progression of hepatoblastoma by activating Wnt/β-catenin signaling pathway. Zhang et al. (2019) observed that miR-320b was downregulated in non-small cell lung cancer (NSCLC) patients and the overexpression of miR-320b inhibited cell proliferation, invasion and induced cell apoptosis in NSCLC cells. miR-320d was downregulated in the serum of hepatocellular carcinoma (HCC) patients and may be a potential non-invasive biomarker for the diagnosis and prognosis of HCC (Li et al., 2020).